CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 773 enrolled / 773 target
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07550712
NCT07550712N/ACompletedHigh Momentum (34.9/mo)Completion was 22mo ago

A Study to Evaluate the Clinical Performance of VeriSee GLC for Screening of Glaucoma Suspect Using Color Fundus Images

Acer Medical Inc.·observational·Posted Apr 24, 2026·Updated Jun 25, 2026

In Brief

An observational study for Glaucoma. Completed, enrolled 773 participants across 1 site.

Signals

Enrolling ahead of pace

Detailed Summary

The goal of this observational study is to evaluate the clinical performance of VeriSee GLC for identifying glaucoma suspects using color fundus images in adult participants. The main questions it aims to answer are: * What are the sensitivity and specificity of VeriSee GLC for detecting glaucoma suspects based on fundus images? * How does the performance of VeriSee GLC compare with the reference standard defined by the majority consensus of three independent evaluators? Researchers will compare the screening results generated by VeriSee GLC with the reference standard to assess its diagnostic performance. This retrospective study will use previously collected fundus images. VeriSee GLC performs automated image analysis to identify glaucomatous signs, including retinal nerve fiber layer (RNFL) defects, vertical cup-to-disc ratio (VCDR) enlargement, and rim-to-disc ratio (RDR) changes. The output is intended to assist healthcare professionals in identifying glaucoma suspects for referral, rather than providing a definitive diagnosis.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma
CountriesTaiwan
Collaborators--

Timeline

N/ACompletedFinished
20252026
First PostedApr 24, 2026
Enrollment StartAug 26, 2024
Primary CompletionAug 26, 2024
Study CompletionDec 27, 2024
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 2 months ago